Evaluation of a lateral flow assay-based IFN-γ release assay as a point-of-care test for the diagnosis of latent tuberculosis infection.
Hoon Hee LeeDong Hwan ChoiJeong-Ran KimYoung Gyun KimKyung Wook JoTae Sun ShimPublished in: Clinical rheumatology (2021)
The ichroma™ IGRA-TB could be used as a point-of-care test for LTBI screening in IMID patients before starting biologics, especially in resource-limited settings. Key Points • The ichroma™ IGRA-TB is an automated fluorescence lateral flow assay-based IGRA. • The test has advantages like short turn-around time, low-cost, and ease of use. • The ichroma™ IGRA-TB showed high agreement with the QuantiFERON-TB Gold In-Tube in patients with chronic immune-mediated inflammatory diseases before starting biologics.
Keyphrases
- mycobacterium tuberculosis
- low cost
- high throughput
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- pulmonary tuberculosis
- prognostic factors
- peritoneal dialysis
- dendritic cells
- patient reported outcomes
- living cells
- fluorescent probe
- hiv aids
- human immunodeficiency virus
- energy transfer